Expert consensus on the clinical application of Xuanfei Baidu granule

Author:

Liu Qingquan1,Zhang Hongchun2,Wang Chengxiang3,Miao Qing4,Yang Fengwen56,Huang Yuhong7,Zheng Wenke56,

Affiliation:

1. Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China

2. China-Japan Friendship Hospital, Beijing, China

3. The Third Affiliated Hospital Beijing University of Chinese Medicine, Beijing, China

4. Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

5. Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China

6. Haihe Laboratory of Modern Chinese Medicine, Tianjin, China

7. Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China

Abstract

Xuanfei Baidu granule is an effective prescription for COVID-19, which is modified from classical famous prescriptions. In order to further standardize clinician’s rational use of Xuanfei Baidu granule, enhance clinical efficacy, improve rational medication level, and let it play a more significant role, the frontline clinical experts are invited for discussion on the major functions, usage, adverse reactions, and considerations of Xuanfei Baidu granule to form the consensus. The consensus is that: Xuanfei Baidu granule has the efficacy of promoting the lung and resolving dampness, clearing heat and removing pathogeneses, purging the lung and depoisoning; it can be used for the treatment of patients with mild, moderate, and heavy COVID-19 and other common upper respiratory tract infectious diseases such as influenza; acute tracheitis and bronchitis and community-acquired lower respiratory tract infectious diseases all belong to damp-toxin constraint in the lungs, Xuanfei Baidu granule can relieve cough, expectoration, and other symptoms caused by an acute exacerbation of the chronic obstructive pulmonary disease, with definite clinical efficacy and good safety. According to the principles of evidence-based medicine, this expert consensus will be updated regularly.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference19 articles.

1. Clinical and pharmacological research progress of “Three Drugs and Three Prescriptions” in the treatment of COVID-19.;Gao;Chin Sci Bull,2022

2. Investigation and analysis of traditional Chinese medicine syndromes of 2 135 Patients with Novel Coronavirus Pneumonia.;Zheng;J Tradit Chin Med,2021

3. Novel Coronavirus Pneumonia expert consensus on prevention and treatment of Chinese patent medicine.;Chin J Integr Tradit West Med,2022

4. Clinical Observation of Xuanfei Baidu decoction in treating severe patients of Novel Coronavirus Pneumonia.;Li;Chin J Chin Mater Med,2022

5. Evaluation of clinical efficacy of Xuanfei Baidu granule in treating Omicron strain infected Novel Coronavirus Pneumonia.;Pang;Tianjin J Tradit Chin Med,2022

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3